• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Windtree Therapeutics

Windtree, Eleison tout feasibility study results

June 5, 2019 By Nancy Crotti

Windtree Therapeutics (OTCQB:WINT) and Eleison Pharmaceuticals have announced positive results of a feasibility study using Windtree’s aerosol delivery system (ADS) to deliver Eleison’s inhaled lipid cisplatin (ILC) for lung cancer. In the study, the ADS technology produced in 20 minutes approximately the same volume of aerosolized ILC that required approximately two hours to produce in […]

Filed Under: Clinical Trials, Drug-Device Combinations, Oncology, Pharmaceuticals, Research & Development, Uncategorized Tagged With: Eleison Pharmaceuticals, Windtree Therapeutics

Windtree Therapeutics implements 1-for-20 reverse split

December 22, 2017 By Sarah Faulkner

Windtree Therapeutics

Windtree Therapeutics (NSDQ:WINT) said today that it implemented a 1-for-20 reverse stock split of its issued and outstanding common stock. The reverse split was approved in November by the holder of the majority of the company’s shares without a meeting of shareholders, according to the Warrington, Penn.-based company. Windtree’s stock began trading today on a split-adjusted […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Windtree Therapeutics

Windtree Therapeutics reports Phase II data for inhaled surfactant

June 29, 2017 By Sarah Faulkner

Windtree Therapeutics

Windtree Therapeutics (NSDQ:WINT) reported data today from the 221-patient Phase IIb trial of its aerosolized KL4 surfactant for the treatment of respiratory distress syndrome in premature infants. The Aerosurf trial evaluated aerosolized KL4 surfactant administered to premature infants 28 to 32 weeks gestational age in 2 dose groups with up to 2 repeat doses, compared […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pediatrics, Pharmaceuticals, Respiratory Tagged With: Windtree Therapeutics

Medtech stories we missed this week: June 23, 2017

June 23, 2017 By Danielle Kirsh

missed medtech

From Guardant suing Foundation Medicine to Interson receiving 510(k) clearance for ultrasound probes, here are medtech stories we missed this week but thought were still worth mentioning. 1. Guardant levels false advertising suit against Foundation Medicine Guardant Health announced in a June 22 press release that it has filed a lawsuit against Foundation Medicine for […]

Filed Under: Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: EndoStim, Foundation Medicine Inc., Guardant Health, Interson, Lee's Pharmaceutical, Meditech, medtech, Rhythm, tso3, Windtree Therapeutics

Windtree touts preclinical data from influenza study for aerosolized surfactant

February 16, 2017 By Sarah Faulkner

Windtree Therapeutics

Windtree Therapeutics (NSDQ:WINT) said today that a preclinical influenza study demonstrated that its aerosolized KL4 surfactant reduced lung inflammation and improved overall survival in ferrets. In the preclinical study, researchers compared Windtree’s aerosolized KL4 surfactant with a daily oral dose of oseltamivir, an antiviral, and placebo controls. Following exposure to the influenza virus, investigators evaluated […]

Filed Under: Featured, Pharmaceuticals, Preclinical Trials, Wall Street Beat Tagged With: Windtree Therapeutics

Windtree touts inhaled therapy for infants with respiratory distress syndrome

November 29, 2016 By Sarah Faulkner

Windtree Therapeutics

Windtree Therapeutics (NSDQ:WINT) today released data from a phase IIa trial evaluating its inhaled Aerosurf lucinactant designed for premature infants with respiratory distress syndrome. Results from the trial were presented at the 6th International Congress of European Neonatal and Perinatal Societies in Valencia, Spain. Premature babies often lack adequate surfactant – a naturally occurring substance that reduces the surface […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pediatrics, Pharmaceuticals, Respiratory Tagged With: Windtree Therapeutics

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS